Promoting Excellence in Education, Research,
and Patient Care in the Rapidly Evolving
Management of Gastrointestinal Cancer
International Society of
Gastrointestinal Oncology
isgioEstablished 2003
2015 Gastrointestinal Oncology Conference Review

2015 Gastrointestinal Oncology Conference
October 22-23, 2015 - Arlington, VA

Please click on abstract title to review abstract PDF file (opens in a new window).

ESOPHAGEAL/GASTRIC CANCER
Adjuvant Therapy in Gastric Cancer: East vs West - Operate First, Chemotherapy Later
Kohei Shitara, MD
Postoperative Treatment of T3N1 GEJ Cancer after Carboplatin/Paclitaxel/RT: More is Not Better, Observation is Standard
David H. Ilson, MD, PhD
Adjuvant Chemotherapy Treatment for Patients with Resected Esophageal and GEJ Cancers After Preoperative Concurrent Chemotherapy and Radiation Therapy
A. Craig Lockhart, MD, MHS
Esophagogastric Cancer: Molecular Subtypes and Implications for Targeted Therapies
Adam Bass, MD
HEPATOBILIARY CANCER
Role of Stereotactic Body Radiation Therapy (SBRT) in Intrahepatic Malignancies
Jeffrey Meyer, MD, MS
Roles of Novel Biologics in Biliary Cancers
Maeve Lowery, MD
Protons offer reduced normal-tissue exposure for patients receiving stereotactic body radiation therapy (SBRT) for liver tumors:
A comparative study based on RTOG 1112

Matthew Knecht, MD, Ian Gordon, Sara Leeds, Roger Grove, Anh Ly, Baldev Patyal, Jerry D Slater, Gary Y Yang
ADVANCED COLON CANCER
Is There an Optimal Treatment Sequence in the Palliative Management of mCRC? What Have we Learned From FIRE-3 and 80405?
Brandon Smaglo, MD
Phase IIa Trial of the Intraperitoneal Implantation of Agarose-Agarose Macrobeads Containing Mouse Renal Adenocarcinoma Cells in the Treatment of Advanced Stage, Treatment-Resistant Metastatic Colorectal Cancer: LDH as a Biomarker of Response and Overall Survival
Barry H. Smith, M.D., Ph.D.; Allyson J. Ocean, M.D.; Zoe Andrada, FNP; Angelica Nazarian, M.D.; Nathaniel Berman, M.D.; Thomas J. Fahey, M.D.; Lawrence S. Gazda, Ph.D.; Tapan Parikh, MBBS, MPH; Joanne Thomas, RN, MSN, MPH; Madeline Wiles, B.S.; Eugene Akahoho, B.S.; Anna Arreglado, M.D., MPH; Jia Lu, M.S.; David J. Wolf, M.D., FACP
LUME-Colon 1: a Randomized, Double-Blind, Phase III Study of Nintedanib plus Best Supportive Care (BSC) versus Placebo plus BSC in Patients with Metastatic or Locally Advanced Colorectal Cancer (CRC) Refractory to Standard Therapies
Yoshino T, Tabernero J, Oum'Hamed Z, Van Cutsem E
LOCALIZED/ADJUVANT COLORECTAL CANCER
The Role of Aspirin in Adjuvant Therapy of CRC
Jeffrey Meyerhardt, MD, MPH
NEUROENDOCRINE TUMORS (NET)
177-Lu-Dotatate Significantly Improves Progression-Free Survival in Patients with Midgut Neuroendocrine Tumors:
Results of the Phase III NETTER-1 Trial

Jonathan Strosberg, Edward Wolin, Beth Chasen, Matthew Kulke, David Bushnell, Martyn Caplin, Richard P. Baum, Erik Mittra, Timothy Hobday, Andrew Hendifar, Kjell Oberg, Maribel Lopera Sierra, Dik Kwekkeboom, Philippe Ruszniewski, Eric Krenning. [on behalf of the NETTERN1 study group]
Safety and Efficacy of Everolimus in Advanced Nonfunctional Neuroendocrine Tumors (NET) of Lung or Gastrointestinal (GI) Origin:
Findings of the Randomized, Placebo- Controlled, Double-blind, Multicenter, Phase 3 RADIANT-4 Study

James C. Yao, Nicola Fazio, Simron Singh, Roberto Buzzoni, Edward Wolin, Jiri Tomasek, Markus Raderer, Harald Lahner, Maurizio Voi, Lida Pacaud, Nicolas Rouyrre, Carolin Sachs, Juan W. Valle, Gianfranco Delle Fave, Eric Van Cutsem, M.E.T. Tesselaar, Yasuhiro Shimada, DoNYoun Oh, Jonathan Strosberg, Matthew H. Kulke, Marianne E. Pavel [for the RAD001 in Advanced Neuroendocrine Tumors, Fourth Trial (RADIANTN4) Study Group]
PANCREATIC CANCER
Pancreatic Cancer: How to Select the Optimal Systemic Therapy for Patients with Metastatic Disease
Andrew H. Ko, MD
ABSTRACTS SELECTED FOR POSTER PRESENTATIONS
ESOPHAGEAL/GASTRIC CANCER
Precision Cancer Medicine Using Induced Pluripotent Stem Cells (iPSCs) Encoded with Anti-GRP78 shRNA Induce Apoptosis after a Gene-Silencing Bystander Effect Circumventing Angiogenesis, and Metastatic Spread in Advanced Chemoresistant Gastrointestinal Stromal Tumors (GIST)
Prof John N. Giannios
Malignant PEComa of Stomach: A Rare Malignancy
Mehandar Kumar, MD, Vinod Kumar, MD, Vanessa Abrina, MD, Supreet Kaur, MD, Abhishek Kuma, MD
ALK Positive Large B-cell Lymphoma of the Stomach: A Case Report and Review of the Literature
Jo-Heon Kim
HEPATOBILIARY CANCER
Changes in Tumor Enhancement on Contrast-Enhanced CT Correlate with Survival in Patients with Hepatocellular Carcinoma Treated with Sorafenib
Nicholas Patchett MD, Alessandro Furlan MD, J. Wallis Marsh MD, MBA
Survival of Colorectal Cancer Patients in Urban and Rural Areas in the State of Kentucky
Raymond Elsoueidi, MD
Combined Nanomedicine,Antisense-Tx Immunomolecular-Targeting inhibits Epigenomic Anti-Apopoptotic Mechanisms Leading to Eradication of CSCs and mCRC Cells
Prof John N Giannios
Treatment with Panitumumab in Patients with Metastatic Colorectal Cancer with Hypersensitivity Reaction after Cetuximab Treatment
Z. Petrovic, D. Tarabar, N. Manojlovic, R. Doder
NEUROENDOCRINE TUMORS (NET)
Does the Addition of Adjuvant Intraoperative Post-Dissection Tumor Bed Chemotherapy During GI Neuroendocrine Tumor Debulking Benefit Patients?
YiNZarn Wang , Aman Chauhan, Robert A Ramirez, David T Beyer, Melissa A Stevens, J Philip Boudreaux, Eugene A Woltering and Lowell Anthony
Neuroendocrine Tumors in First Three Decades of Life
Ramya Thota, Chanjuan Shi, Dana Cardin, Ronald Walker, Jordan Berlin
Economic Benefits Associated with Resolution or Improvement of Carcinoid Syndrome Symptoms Following Treatment with Above-Standard Dose of Octreotide-LAR in Patients with Neuroendocrine Tumors: Assessment Based on Data from a Multicenter Retrospective Chart Review Study
Lynn Huynh, MPH, MBA, DrPH; Todor Totev, BSc ; Francis Vekeman, MA Maureen P. Neary, PhD, MS ; Mei S. Duh, MPH, ScD ;Matthew H. Kulke, MD Al B. Benson, MD
PANCREATIC CANCER
The Hippo Transducer TAZ Promotes Epithelial-Mesenchymal Transition and Progression in Pancreatic Cancer
Dacheng Xie, Jiujie Cui, Tian Xia, Zhiliang Jia, Keping Xie, Yong Gao, and Ming Quan
The phase II LAPACT trial of nab-paclitaxel (nab-P) plus gemcitabine (Gem) in patients with locally advanced pancreatic cancer (LAPC)
Philip Philip, Scot Dowden, Javier Sastre, Venu Bathini, Dana Cardin, Jill Lacy, Matthew Dugan, Alberto Sobrero, Charles Henderson, Morton Coleman, Edward Kim, Wen Wee Ma, Sheryl Koski, Christophe Borg, Giuseppe Tonini, Fernando Rivera, Louis Kayitalire, Jack Shiansong Li, Pascal Hammel
nab-Paclitaxel (nab-P) plus gemcitabine (Gem) vs Gem alone as adjuvant therapy for resected pancreatic cancer (PC) in a global phase III trial (APACT)
Margaret A. Tempero, Dana Cardin, Andrew Biankin, David Goldstein, Malcolm Moore, Eileen M. O'Reilly, Philip Philip, Hanno Riess, Teresa Macarulla, Lotus Yung, Mingyu Li, Brian Lu